New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Editas Medicine, Inc. (EDIT) vs SAB Biotherapeutics, Inc. (SABS)

Editas Medicine, Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Editas Medicine, Inc. and SAB Biotherapeutics, Inc. are of similar size ($263.9M and $262.2M). Editas Medicine, Inc. grew revenue faster over the last twelve months: 7.42% against −56.7%. Editas Medicine, Inc. has the higher net margin (−145.0% vs −1,450.3%) and the higher return on invested capital (0.00% vs −48.4%). Across the 16 metrics below, Editas Medicine, Inc. leads on 10 and SAB Biotherapeutics, Inc. on 6.

Valuation

Metric EDIT SABS Biotechnology median
P/E n/m n/m 8.49
P/S 5.02 161.56 8.56
P/B 2.96 1.25 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 1.21 99.47 8.00
Earnings yield (38.18%) (32.95%) (35.81%)
Free cash flow yield (44.01%) (22.34%) (25.41%)

Profitability

Metric EDIT SABS Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (151.71%) (1,647.03%) 0.00%
Net margin (144.95%) (1,450.32%) 0.00%
Free cash flow margin (221.15%) (1,344.29%) 0.00%
Return on equity (147.44%) (47.62%) (51.58%)
Return on assets (34.30%) (42.73%) (45.91%)
Return on invested capital 0.00% (48.38%) 0.00%

Growth

Metric EDIT SABS Biotechnology median
Revenue growth (TTM) 7.42% (56.68%) 7.20%
EPS growth (last fiscal year) 37.50% 78.53% 29.04%
Revenue growth, 5-year CAGR (14.89%) — 9.54%
Net income growth, 5-year CAGR — (26.69%) 0.00%

Health

Metric EDIT SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 2.82 7.28 4.79
Net debt to EBITDA 0.94 2.03 1.01

Dividend

Metric EDIT SABS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EDIT SABS Biotechnology median
Market cap 263.92m 262.16m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack